The New Economy and its Winners Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The New Economy and its Winners

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Lizzie Tudor who wrote (11573)	5/16/2002 10:17:28 AM
From: Bill Harmond	Read Replies (1) of 57684

NPS Pharm downgraded by Merrill on Preos concerns (NPSP) 31.43: Merrill Lynch downgrades to near-term BUY from Strong Buy; believes timing of Preos product launch has become increasingly uncertain; says last night's 10-Q revealed that company only has enough Preos to meet clinical trial requirements into Q3 due to a recent problem at its contract fill & finish manufacturer; believes this could ultimately delay the drug's launch. 10:13 ET NPSP NPS Pharm defended by Merrill (21.80 -9.63) -- Update -- Merrill Lynch downgraded stock this morning (see 7:27 comment), now comes to its defense after 30% plunge improves risk/reward; Merrill notes that there are two scenarios with regards to Preos: either manufacturing problems get worked out in 6-7 weeks and stock is worth $39 over the next 12 months, or the Preos study has to be scrapped and restarted, in which case the sales potential is reduced by 1/3rd and launch is pushed out to 2008, in which case it's worth $17.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next